Acepodia Provides Corporate Update and Unveils New Preclinical Allogeneic NK Cell Therapy Pipeline Candidates at BIO Digital 2020 – GlobeNewswire
- First clinical trial site for ACE1702 initiated, with clinical data expected in Q4 2020
- Investigational New Drug clearance expected for ACE1755 in Q1 2021
- Pipeline expansion incorporating CAR technology
- Preclinical data for early stage ACC- and CAR-oNK cell therapy candidates demonstrate promise in models of solid tumors and hematological malignancies
SAN FRANCISCO and TAIPEI, Taiwan, June 08, 2020 (GLOBE NEWSWIRE) — Acepodia, a biotechnology company reshaping the field of cell therapies through a flexible and integrated approach to design and development of effective treatment strategies for cancer, today announced Sonny Hsiao, Ph.D., chief executive officer, will present data from its new integrated preclinical cell therapy pipeline that leverages both its unique antibody cell conjugation technology (ACC) and current chimeric antigen receptor (CAR) technologies in an on-demand presentation at the 2020 BIO Digital Conference being held virtually from June 8-12, 2020.
Details on the on-demand digital presentation can be found below:
Presentation details
Title: Acepodia Company Presentation BIO Digital 2020
Date: June 8-12, 2020
Presenter: Sonny Hsiao, Ph.D., chief executive officer
Location: https://www.bio.org/events/bio-digital
“The first half of this year has so far seen tremendous growth for Acepodia, marked most notably by the initiation of our first clinical trial site for our lead candidate, ACE1702, as well as by the promising preclinical data from our expanded portfolio of cell therapy candidates to be presented at this year’s BIO Digital Meeting,” said Sonny Hsiao. “The therapeutic impact of currently available cell therapies is
Source…